Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Cancer Survival Analysis01:21

Cancer Survival Analysis

298
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
298
Introduction To Survival Analysis01:18

Introduction To Survival Analysis

115
Survival analysis is a statistical method used to study time-to-event data, where the "event" might represent outcomes like death, disease relapse, system failure, or recovery. A unique feature of survival data is censoring, which occurs when the event of interest has not been observed for some individuals during the study period. This requires specialized techniques to handle incomplete data effectively.
The primary goal of survival analysis is to estimate survival time—the time...
115
Comparing the Survival Analysis of Two or More Groups01:20

Comparing the Survival Analysis of Two or More Groups

85
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
85
Kaplan-Meier Approach01:24

Kaplan-Meier Approach

55
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
55
Actuarial Approach01:20

Actuarial Approach

39
The actuarial approach, a statistical method originally developed for life insurance risk assessment, is widely used to calculate survival rates in clinical and population studies. This method accounts for participants lost to follow-up or those who die from causes unrelated to the study, ensuring a more accurate representation of survival probabilities.
Consider the example of a high-risk surgical procedure with significant early-stage mortality. A two-year clinical study is conducted,...
39
Statistical Software for Data Analysis and Clinical Trials01:12

Statistical Software for Data Analysis and Clinical Trials

314
Statistical software is pivotal in data analysis and clinical trials by providing tools to analyze data, draw conclusions, and make predictions. These software packages range from simple data management applications to complex analytical platforms, supporting various statistical tests, models, and simulation techniques. Their significance lies in their ability to handle vast amounts of data with precision and efficiency, enabling researchers to validate hypotheses, identify trends, and make...
314

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Novel High-Efficacy Antimicrobial Peptides Derived from Myxinidin and their Therapeutic Efficacy in Bacterial Pneumonia.

Journal of medicinal chemistry·2026
Same author

Elucidating the Multifaceted Influence Pathway of Spin Regulation on Carrier Dynamics and O<sub>2</sub> Transformation in a Chiral LDO Photocatalytic Framework.

Small (Weinheim an der Bergstrasse, Germany)·2026
Same author

The Health of Nations Fund: Financing global drug development.

PLOS global public health·2026
Same author

Estimating the global inventory of deprioritized clinical-stage drug development programs: Toward a market for shelved assets.

Drug discovery today·2026
Same author

Plasmid-Free, High-Titer De Novo Adenine Production in <i>Escherichia coli</i> via Modular Pathway Engineering and Adaptive Evolution.

ACS synthetic biology·2026
Same author

Systems Metabolic Engineering of <i>Escherichia coli</i> for High-Titer De Novo β-Thymidine Production via Folate Cycle Enhancement and NADPH Regeneration.

Journal of agricultural and food chemistry·2026

相关实验视频

Updated: May 11, 2025

Predicting Treatment Response to Image-Guided Therapies Using Machine Learning: An Example for Trans-Arterial Treatment of Hepatocellular Carcinoma
04:09

Predicting Treatment Response to Image-Guided Therapies Using Machine Learning: An Example for Trans-Arterial Treatment of Hepatocellular Carcinoma

Published on: October 10, 2018

8.1K

通过统计和机器学习模型预测临床试验的持续时间.

Joonhyuk Cho1,2,3, Qingyang Xu1, Chi Heem Wong1

  • 1MIT Laboratory for Financial Engineering, Cambridge, MA, USA.

Contemporary clinical trials communications
|April 18, 2025
PubMed
概括
此摘要是机器生成的。

使用机器学习预测临床试验持续时间,特别是DeepSurv,提供了准确的见解. 这种方法有助于研究人员优化试验设计,减少药物开发的财务风险.

关键词:
临床试验临床试验是指临床试验的临床试验.考克斯的比例危险模型.功能重要性 功能重要性机器学习是机器学习.对生存分析的分析.

更多相关视频

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment
12:18

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment

Published on: January 11, 2020

7.4K
Implementation of a Real-Time Psychosis Risk Detection and Alerting System Based on Electronic Health Records using CogStack
07:31

Implementation of a Real-Time Psychosis Risk Detection and Alerting System Based on Electronic Health Records using CogStack

Published on: May 15, 2020

6.9K

相关实验视频

Last Updated: May 11, 2025

Predicting Treatment Response to Image-Guided Therapies Using Machine Learning: An Example for Trans-Arterial Treatment of Hepatocellular Carcinoma
04:09

Predicting Treatment Response to Image-Guided Therapies Using Machine Learning: An Example for Trans-Arterial Treatment of Hepatocellular Carcinoma

Published on: October 10, 2018

8.1K
A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment
12:18

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment

Published on: January 11, 2020

7.4K
Implementation of a Real-Time Psychosis Risk Detection and Alerting System Based on Electronic Health Records using CogStack
07:31

Implementation of a Real-Time Psychosis Risk Detection and Alerting System Based on Electronic Health Records using CogStack

Published on: May 15, 2020

6.9K

科学领域:

  • 生物统计学 生物统计学
  • 医疗保健中的机器学习
  • 临床试验管理 临床试验管理

背景情况:

  • 临床试验的持续时间显著影响药物开发时间表和成本.
  • 准确预测试验持续时间对于有效的资源配置和风险管理至关重要.
  • 预测临床试验持续时间的现有方法在准确性和范围上有局限性.

研究的目的:

  • 开发和验证临床试验持续时间的先进预测模型.
  • 通过使用综合数据集,确定影响临床试验持续时间的关键因素.
  • 评估机器学习模型,特别是DeepSurv在预测试验持续时间方面的性能.

主要方法:

  • 应用生存分析和机器学习模型.
  • 利用最大的可用数据集进行临床试验持续时间预测.
  • 采用基于神经网络的DeepSurv来提高预测准确度.

主要成果:

  • 与其他模型相比,DeepSurv在预测临床试验持续时间方面表现出卓越的准确性.
  • 确定了影响临床试验长度的关键因素.
  • 开发的方法提供了可靠的预测试验时间表.

结论:

  • 机器学习,特别是DeepSurv,为预测临床试验持续时间提供了一个强大的工具.
  • 通过准确的持续时间预测,优化试验设计可以加快药物测试.
  • 可以在药物开发中降低财务风险,从而有可能增加该部门的投资.